Streetbeat News

Stock Prices

JNJ

Johnson & Johnson's Phase 2 trial of TAR-200 plus cetrelimab shows promising results in bladder cancer treatment, nearly doubling the response rate compared to cetrelimab alone.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:57 am

EXAS

Exact Sciences Corp. presented promising data for its blood-based colorectal cancer screening test at the ESMO Congress, showing high sensitivity and specificity. This development could enhance cancer screening options.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:53 am

REPL

Replimune announced positive primary analysis results from the IGNYTE clinical trial of RP1 in combination with Nivolumab for anti-PD1 resistant melanoma at the 2024 ESMO Congress. The data shows clinically meaningful activity across all subgroups, including those with prior anti-PD1 and anti-CTLA-4 treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:46 am

MRK

Merck's KEYTRUDA, combined with chemoradiotherapy, reduces mortality risk by 33% in high-risk cervical cancer patients, marking a significant advancement in treatment. The KEYNOTE-A18 study is the first Phase 3 trial to show improved survival rates with this combination, with results presented at the ESMO Congress 2024 and published in The Lancet.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:31 am

AXR

CODA

RFIL

VNCE

XCUR

Coda Octopus, Exicure, RF Industries, AMREP, and Vince Holding are stocks to watch as they report earnings or make significant moves. Coda Octopus and RF Industries are expected to report earnings, while Exicure surged after a debt-for-equity exchange. AMREP reported strong earnings growth, and Vince Holding is expected to post a loss.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 6:29 am

AAPL

AMD

CRM

DELL

IBM

MSFT

NOW

NVDA

ORCL

PLTR

QQQ

XLK

Wedbush analyst Daniel Ives suggests that tech stocks are poised for growth as the Federal Reserve begins a rate-cutting cycle. Key players in the AI revolution, such as Nvidia and Microsoft, are expected to drive this growth, with other tech companies like Oracle, ServiceNow, Palantir, Salesforce, Dell, IBM, Apple, and AMD joining the trend. The Invesco QQQ Trust and Technology Select Sector SPDR Fund have shown positive performance, indicating investor optimism despite high valuations.

Portfolio Pulse from Shanthi Rexaline

September 16, 2024 | 6:25 am

MRK

Merck's KEYTRUDA shows a significant 10-year survival advantage over ipilimumab in treating advanced melanoma, with a 34% survival rate compared to 23.6% for ipilimumab. KEYTRUDA reduces the risk of death by 29% and more than doubles the median overall survival.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:21 am

AZN

AstraZeneca's IMFINZI regimen significantly reduced recurrence and death risks in bladder cancer patients, as shown in the NIAGARA Phase III trial. This is the first immunotherapy regimen to show such improvements in overall survival in this setting.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:13 am

ORCL

Annapurna Interactive, owned by Megan Ellison, daughter of Oracle co-founder Larry Ellison, faces a mass resignation of its entire staff, including top executives. This follows failed talks of a spinoff. Despite internal tensions, the company aims to support its partners and expand in the interactive space. Meanwhile, Oracle has seen growth in the cloud and AI sectors, boosting Larry Ellison's wealth.

Portfolio Pulse from Ananya Gairola

September 16, 2024 | 4:24 am

AAPL

Apple Inc. (NASDAQ:AAPL) has increased the battery replacement cost for the iPhone 16 Pro and iPhone 16 Pro Max by $20, now priced at $119. This follows previous price hikes for other models and devices. The change highlights Apple's ongoing adjustments in service pricing.

Portfolio Pulse from Ananya Gairola

September 16, 2024 | 2:53 am